Pengaruh penggunaan metotreksat terhadap kadar bun dan kreatinin pasien reumatoid artritis di RSUP Dr. Sardjito Yogyakarta - Widya Mandala Catholic University Surabaya Repository

BAB 5 KESIMPULAN

  5.1 Kesimpulan

  Berdasarkan hasil penelitian yang berjudul pengaruh penggunaan metotreksat terhadap kadar BUN dan kreatinin pasien artiritis rheumatoid di RSUP. Dr. Sardjito Yogyakarta diperoleh kesimpulan sebagai berikut: Penggunaan metotreksat tidak menyebabkan peningkatan terhadap kadar BUN dan kreatinin pada pasien artritis reumatoid di RSUP. Dr. Sardjito Yogyakarta.

  5.2 Saran

  Berdasarkan hasil penelitian yang telah dilakukan, dapat disarankan hal sebagai berikut: Penelitian dapat dilakukan dengan rentang waktu yang lebih lama (1 tahun) untuk mengamati pengaruh penggunaan metotreksat dalam pemakaian jangka panjang dan menilai pengaruh yang terjadi terhadap kadar BUN dan kreatinin pasien artritis reumatoid di RSUP. Dr. Sardjito Yogyakarta.

DAFTAR PUSTAKA

  Afriyanti, F.N. 2009, ‘Tingkat Pengetahuan Lansia Tentang Penyakit Rheumatoid Arthtritis di Panti Sosial Tresna Werdha (PSTW) Budi Mulia 1 Cipayung Jakarta Tahun 2009

  ’,Skripsi, Universitas Islam Negeri, Jakarta. Agency for Healthcare Research and Quality (AHRQ). 2008,

  ‘Rheumatoid

  Arthritis Medicines A Guide for Adults

  ’,Diakses pada 10 Oktober 2016, http://www.effectivehealthcare.ahrq.gov/repFiles/ RheumArthritisConsumerGuide_Singlepage.pdf.

  Ahmed, W., Zaki, A., Nabil, T. 2015,Revention of methotrexate-induced nephrotoxicity by concomitant administration of garlic aqueous extract in rat, Turkish Journal of Medical Sciences. 45(3): 507-16. Alamanos, Y.and Drosos, A.A. 2005, Epidemiology of Adult Rheumatoid Arthritis, AutoimmunityReviews, 4(3):130-6.

  American College of Rheumatology. 2015,

  ‘American College of Rheumatology Guideline for the Treatment of Rheumatoid

  Diakses pada

  10 Oktober 2016,

  Arthritis’,

  https://www.google.co.id/url? sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0ahUKEwiBo- bi7TQAhUYS48KHXioA6AQFgghMAA&url=http%3A%2F%2F www.rheumatology.org%2FPortals%2F0%2FFiles%2FACR%252 02015%2520RA%2520Guideline.pdf&usg=AFQjCNEfUJP8gQo w5Ag3FDDiDkBXf6nEQ&sig2=y0t_Ttorr1HGmH1JQVeEBg&ca d=rja. Anonim, 2012,

  ‘Patient information on methotrexate’. Australian Rheumatology Association (ARA), Australia,pp 1. Anonim, 2015, pada

  27 Januari

  ‘Methotrexate’,Diakses

  2018rug-and-Medication- Information. Aronoff, G.R., Bennett, W.M., Morrison, G., Golper, T.A., Pulliam, J., Wolfson, M., Singer, I. 2007, Drug Prescribing in Renal Failure:

  th Dosing Guidelines for Adults and Children , 5 ed,PA: American College of Physicians, Philadelphia.

  Arthritis Foundation, 2015,

  ‘Arthritis Foundation Scientific Strategy 2015- 2020 ’, Diakses pada 10 Oktober 2016, http://www.arthritis.org/

  Documents/arthritis-foundationscientific-strategy.pdf Badley, E, DesMeules, M. 2003. M. Introduction. In: Badley E, DesMeules

  M, eds. Arthritis in Canada. An ongoing challenge. Ottawa: Health Canada:1-6. Bannwarth, B., Pe´hourcq, F., Schaeverbeke, T., Dehais, J. 1996, Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis, Clin Pharmacol, 30:194 –210. Beck, O., Seideman, P., Wennberg, M. and Peterson, C. 1991, Trace analysis of methotrexate and 7-hydroxymethotrexate in human plasma and urine by a novel (HPLC) method, Ther. Drug. Monit, : 528-532.

13 Bergström, U. 2011.

  ‘Clinical and epidemiologic aspects of Rheumatoid

  Arthritis ’. Special emphasis on cardiovascular outcome and risk

  factors Unit of Rheumatology, Dept of Clinical Sciences, Malmö.pp 21. Chakrabarti, S., Lekontseva, O. and Davidge, S.T. 2008, Estrogen is a modulator of vascular inflammation,IUBMB Life, 60: 376

• –382. Choy, E. 2012, Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis, .

  Rheumatology

  doi:10.1093/rheumatology/kes113.51:v3-v11 Costa, E., Rocha, S., Pereira, P.R., Castro, E., Reis, F., Teixeira, F., Miranda, V., Faria, M.D.S., Loureiro, A., Quintanilha, A., Belo, L. and Silva, A.S. 2008,Cross-talk Between Inflammation,

  Coagulation/Fibrinolysis and Vascular Access in Hemodialysis Patients, The Journal of Vascular Access, 9: 248-253. Cross, M., Smith, E., Hoy, D., Nolte, S., Ackerman, I., Fransen, M.,

  Bridgett, L., Williams, S., Guillemin, F., Hill, C.L., Laslett, L.L., Jones, G., Cicuttini, F., Osborne, R., Vos, T., Buchbinder, R., Woolf A., March L.. 2014,The Global Burden of Hip and Knee Osteoarthritis: Estimates from the Global Burden of Disease 2010 Study, Ann Rheum Dis, 73: 1323-1330.

  Cutolo, M., Sulli, A., Pizzorni, C., Seriolo, B., Straub, R.H. 2001, Antiinflammatory mechanisms of methotrexate in rheumatoid arthritis, Ann Rheum Dis, 60:729

• –735. Daud, R. 2000, Tinjauan Kepustakaan: Diagnosis dan Penatalaksanaan Artritis Reumatoid. Cermin Dunia Kedokteran. 129:9.

  Furst, D.E. 1997, The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases, Br J Rheumatol. 36:1196

• –1204. Gaies, E., Jebabli, N., Trabelsi, S., Salouage, I., Charfi, R., Lakhal, M.,

  Klouz, A. 2012, Methotrexate Side Effects: Review Article, J 3:125. doi:10.4172/2157-7609.1000125 Drug Metab Toxicol. _th

  Ganong, W.F., 2001.Buku Ajar Fisiologi Kedokteran, Ed 20 .McGraw-Hill Companies, New York, 677, 696. Gilani S.T., Khan, D.A., Khan, F.A., and Ahmed, M. 2012. Adverse effects of low dose methotrexate in rheumatoid arthritis patients. J Coll

  Physicians Surg Pak , 22(2):101 –104.

  Gordon, M.M., Hampson, R., Capell, H.A., and Madhok, R., 2002, Illiteracy in Rheumatoid Arthritis Patients as Determined by the Rapid Estimate of Adult Literacy in Medicine (REALM) Score, , 41:750-754.

  British Society for Rheumatology

  Guyton, A.C and Hall, J.E. 2006, ‘Glomerular Filtration, Renal Blood Flow, and Their Control’, in Guyton, A.C and Hall, J.E., Textbook of th

  Medical Physiology, 11 ed., Elsevier Saunders Inc., Philadelphia, pp 307-311. Güler, N., Tander, B., Kisacik, B., Utku, U., Cevlk, A., Vehbi E., Gülçin E.,

  Özgür E., Rahmi A., Ferhan C. 2008, Low dose methotrexate associated pancytopenia in a patient with rheumatoid arthritis, Turk

  J Phys Med Rehab , 54: 79-81.

  Hernández,A.M, Liang, M.H., Willett, W.C., Stampfer, M.J., Colditz, G.A., Rosner, B., Roberts, W.N., Hennekens, C.H., Speizer, F.E. 1990, Reproductive factors, smoking and the risk for rheumatoid arthritis, Epidemiology,1:285

• –289. Jonsson, B. 2008,Patient access to rheumatoid arthritis treatments,The

  :S35 European Journal of Health Economics,8 (Suppl 2) –S38. Kraag, G.R. 1989, Clinical Aspects in Rheumatoid Arthritis, Triangle, 29: 15-24.

  Li, X., Abe, E., Yamakawa, Y., Yoneda, G., Fujino, R., Mami Y., Yuumi I., Hirofumi J., Hideyuki S. 2016, Effect of Administration Duration of Low Dose Methotrexate on Development of Acute Kidney Injury in Rats,J Kidney, 2: 130.

  Longo, D.L. MD., Kasper, DL. Hauser SL, Jameson J., Loscalzo, J., Dennis L. MD., Anthony SF. MD., Eugene B. MD., 2012,

  ‘Rheumatoid Arthritis

  ’, Harrison’s Principle of Internal Medicine, 8th ed., McGraw-Hill Companies, Inc., USA. Mäkinen, Heidi. 2008. Disease Activity and Remission in Rheumatoid

  Arthritis. Comparision of Available Disease Activity Measures and

  Development of a Novel Disease Activity Index- the Mean Overall ). Kuopio University. Index for Rheumatoid Arthritis (MOI-RA

  Mancintyre, P. E., and Schug, S.A. 2007,Acute Pain Management A Partical Guide , 3rd ed. Saunders Elsevier, China, Page: 216-220.

  Marieb, Elaine, N., and Hoehn, K. 2010, Human Anatomy & Physiology, _th 8 ed . Benjamin Cummings, USA. McPhee, S.J. and Ganong, W.F. 2006,

  ‘Renal Disease’ in McPhee, S.J and Ganong, W.F.,Pathophysiology of Disease: An Introduction to

  Mc Graw Hill Companies Inc.,New

  Clinical Medicine, 5th ed.,

  York Mota, L.M., Brenol, C.V., Palominos, P., Pinheiro, Gda.R.. 2015,

  Rheumatoid arthritis in Latin America: the importance of an early diagnosis. Clin Rheumatol, 34(1): 29

• –44. Muchid, A. 2006. Pharmaceutical Care untuk Pasien Penyakit Arthiritis

  Rematik . Direktorat Bina Farmasi Komunitas dan Klinik, Ditjen Bina Kefarmasian dan Alat Kesehatan, Jakarta.hal 1.

  Nainggolan, O. 2009, Prevalensi dan Determinan Penyakit Rheumatik di Indonesia. Majalah Kedokteran Indonesia, 59: 587-594. Nasution, A.R dan Sumarlyono. 2009, Introduksi Reumatologi Dalam

  :Buku Ajar Ilmu Penyakit Dalam. Jakarta: Fakultas Kedokteran

  Universitas Indonesia. V: 2353-9 NCCCC - National Collaborating Centre for Chronic Conditions. 2009. ‘Rheumatoid arthritis: national clinical guideline for management and treatment in adults’ Royal College of Physicians: London.

  Pagana, K.D and Pagana, T.J. 2002,Manual of Diagnostic and Laboratory , Mosby Inc., Missouri.

  Test

  Pearce. 1995,Anatomi dan Fisiologi untuk Paramedis, PT Gramedia Pustaka Utama, Jakarta. Perhimpunan Reumatologi Indonesia. 2014. Rekomendasi Perhimpunan

  Reumatologi Indonesia Untuk Diagnosis dan Pengelolaan Artritis Reumatoid: Perhimpunan Reumatologi Indonesia. Price, SA, Wilson, LM. 2005. Patofisiologi : Konsep Klinis Proses-Proses

  Penyakit . Volume 2 Ed/6. Hartanto H, Susi N, Wulansari P,

  Mahanani DA, editor. Jakarta: EGC, hal. 1385-1391 Pollard, L., Choy, E.H., and Scott, D.L. 2005, The Consequences of

  Rheumatoid Arthritis: Quality of Life Measures in The Individual Patient, Clinical Experimental Rheumatology, 23:S43-S52. Rachel, A. Burke & Nicole D. White. 2014. Biologic Disease-Modifying . PSAP: Chronic Illnesses II.

  Antirheumatic Drugs

  Schneider, Matthias, Krüger, and Klaus. 2013,Rheumatoid Arthritis

  —Early Diagnosis and Disease Management . Deutsches Ärzteblatt

  International. Jerman. Schuna, A.A., Dipiro, J.T., Talbert, R.L., Yee, G.C. Matzke, G.R., Wells,

  B.G. & Posey, L.M., (Eds), 2008, ‘Rheumatoid Arthritis’ in

  Schuna, A.A., Dipiro, J.T., Talbert, R.L., Yee, G.C. Matzke, G.R., Wells, B.G. & Posey, L.M., (Eds),Pharmacotherapy A

  Pathophysiologic Approach, 7th Edition , McGraw Hill, Medical Publishing Division, New York, 1505-1515.

  Silman, A.J. 2002,The Changing Face of Rheumatoid Arthritis: Why the Decline in Incidence? Arthritis & Rheumatism, 46(3): 579-581. Smolen, J.S., Landewé, R., Breedveld, F.C., Buch, T, Burmester, G.R.,

  Dougados, M. 2014, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, Ann Rheum

  Dis , 73(3):492 –509.

  Statistics Netherlands. 2010, CBS StatLine: Reported health and lifestyle.Diakses pada 1 November 2016, http://statline.cbs.nl /StatWeb/selection/?DM=SLEN&PA=03799ENG&LA=EN&VW =T.

  Suarjana, I.N. 2009. Artritis Reumatoid Dalam Buku Ajar Ilmu Penyakit

  Dalam Edisi V. Sudoyo, A.W., Setiyohadi, B., Alwi, I., Simadibrata, M., Setiati, S. Interna Publishing. Jakarta.

  Symmons D.P.

  2005. ‘Looking back: rheumatoid arthritis--aetiology,

  occurrence and mortality ’. Rheumatology (Oxford). Suppl 4:iv14-

  iv17. Tanner, G.A. 2013. Medical Physiology: Renal physiology and Body Fluids.

  Philadelphia. Wolters Kluwer Health/Lippincott Williams & Wilkins. Chapter-22 Kidney Function; pp-393

  Tian, H. and Cronstein, B. N. 2007, Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bulletin of the NYU Hospital for Joint , 65(3):168-73.

  Diseases

  Verdiansah. 2016. Pemeriksaan Fungsi Ginjal. Program Pendidikan Dokter Spesialis Patologi Klinik Rumah Sakit Hasan Sadikin. Bandung.

  Cermin Dunia Kedokteran . 43(2): 148-154.

  Widemann B.C. and Adamson, P.C. 2006, Understanding and managing methotrexate nephrotoxicity, The Oncologist, 11:694-703. Williams, Lippincott & Wilkins. 2011, Professional Guide to

  Pathophysiology , 3rd Ed, Wolters Kluwer Health, Norristown, 435-458.

  Wilson, L.M. and Price, S.A. 1995, Patofisiologi: Konsep Klinis Proses-

Proses Penyakit , Penerbit Buku Kedokteran EGC, Jakarta.

Zhang, S.X., Miao M., Liu, X.Q., Ma, X.W., Wu, X.Y., Li, X.F. 2016, The

  Efficacy and Safety of Low Dose IL-2 Therapy in over-Treated Patients with Rheumatoid Arthritis: A Preliminary Study [abstract], Arthritis Rheumatol, 68 (10): 4-2.